## Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form FWP

### LABORATORY CORP OF AMERICA HOLDINGS

Form FWP October 29, 2013

Filed Pursuant to Rule 433

Registration No. 333-178428

October 29, 2013

#### PRICING TERM SHEET

#### \$700,000,000

\$400,000,000 2.50% Senior Notes due 2018

\$300,000,000 4.00% Senior Notes due 2023

Unless otherwise indicated, terms used but not defined herein have the meanings assigned to such terms in the Preliminary Prospectus Supplement dated October 29, 2013.

**Issuer:** Laboratory Corporation of America Holdings

Expected Ratings (Moody s/S&P)\*: Baa2/BBB

Security: 2.50% Notes due 2018 (the 2018 Notes ) 4.00% Notes due 2023 (the 2023 Notes )

 Principal Amount:
 \$400,000,000
 \$300,000,000

 Maturity Date:
 November 1, 2018
 November 1, 2023

**Coupon:** 2.50% 4.00%

Interest Payment Dates: May 1 and November 1, commencing May 1, May 1 and November 1, commencing May

2014

**Price to Public:** 99.916% 98.726%

**Net Proceeds to Issuer (before expenses):** \$397,264,000 \$294,228,000

**Benchmark Treasury:** 1.375% due September 30, 2018 2.50% due August 15, 2023

Benchmark Treasury Price / Yield:  $100-16 \frac{1}{4} / 1.268\%$  99-30 / 2.507% Spread to Benchmark Treasury: + 125 basis points + 165 basis points

**Reoffer Yield:** 2.518% 4.157%

**Make-Whole Spread:** + 20 basis points + 25 basis points

**Optional Redemption:** The issuer may at its option redeem some or The issuer ma

all of the 2018 Notes at any time or from time to time prior to their maturity, at a redemption price equal to the greater of the principal amount of the 2018 Notes being redeemed plus accrued and unpaid interest to the redemption date or the Make-Whole Amount, as described in the preliminary prospectus supplement, which includes a Make-Whole

Spread.

The issuer may at its option redeem some or all of the 2023 Notes at any time or from time to time prior to August 1, 2023, at a redemption price equal to the greater of the principal amount of the 2023 Notes being redeemed plus accrued and unpaid interest to the redemption date or the Make-Whole Amount, as described in the preliminary prospectus supplement, which includes a Make-Whole Spread.

1, 2014

1

# Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form FWP

On or after August 1, 2023, the issuer may at its option redeem some or all of the 2023 Notes at a redemption price equal to the principal amount of the 2023 Notes being redeemed plus accrued and unpaid interest to the redemption date.

## Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form FWP

CUSIP/ISIN: 50540R AM4 / US50540RAM43 50540R AN2 / US50540RAN26

Trade Date: October 29, 2013

Expected Settlement Date: November 1, 2013

Active Joint Book-Running Managers: Barclays Capital Inc.

Wells Fargo Securities, LLC

Passive Joint Book-Running Managers: Credit Suisse Securities (USA) LLC

Goldman, Sachs & Co.

Co-Managers: Lazard Capital Markets LLC

Fifth Third Securities, Inc.

Merrill Lynch, Pierce, Fenner & Smith Incorporated

U.S. Bancorp Investments, Inc.

\*Note: A security rating is not a recommendation to buy, sell or hold securities, and may be subject to revision or withdrawal at any time. Each of the security ratings above should be evaluated independently of any other security rating.

The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering.

You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Barclays Capital Inc. toll-free at 1-888-603-5847 or Wells Fargo Securities, LLC toll-free at 1-800-326-5897.

Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded. Such disclaimer or notice was automatically generated as a result of this communication being sent by Bloomberg or another email system.